In the national campaign Watch This, O'Neal gets real about living with moderate obstructive sleep apnea (OSA) and the moment he decided to do something about it
EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the start
2 Profitable Stocks for Long-Term Investors and 1 Facing Headwinds
In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mg
The S&P 500 Index ($SPX ) (SPY ) today is up +1.01%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.39%. June E-mini S&P futures (ESM26...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.65%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.59%. June E-mini S&P futures (ESM26...
June S&P 500 E-Mini futures (ESM26) are up +0.71%, and June Nasdaq 100 E-Mini futures (NQM26) are up +1.40% this morning, signaling a rebound from Friday’s selloff on Wall Street as investors stepped...
In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4  lbs (14.4%) and those in post-menopause lost up  to  28.2  lbs  (14.1%)
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity